Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

SA53 is a genetically targeted therapeutic designed to reactivate the tumor suppressor protein p53 commonly referred to as the “Guardian of the Genome by inhibiting the MDM2 protein, which typically ...

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small ...

WATERTOWN, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small ...

**This article was originally published for ROTY Biotech Community subscribers on November 10th but has been updated where necessary. Despite the +68% gain since purchase, I continue to think there's ...

Researchers from the Chinese Academy of Sciences and collaborators reported on the discovery and preclinical characterization of JN-122, a potent spiroindoline derivative that showed a Ki value of 0.7 ...

BROOKLINE, Mass.--(BUSINESS WIRE)--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid ...

ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and ...